Overview
MNOV market data
Price History
MNOV price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.17 – $1.96 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $65.5 · P/B 1.55 · P/S 109.72.
Company news
MediciNova Enrolls 200 Patients In SEANOBI-ALS StudyBenzinga · Jul 15, 2026, 12:08 PM
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightGlobenewswire Inc · Jun 8, 2026, 5:15 PM
MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of GlioblastomaBenzinga · Jun 8, 2026, 12:15 PM
Reported Earlier, MediciNova Reaches Last Patient Last Visit Milestone In Phase 2 MN-001 Tipelukast Trial, Top-Line Data Expected Q3 2026Benzinga · May 27, 2026, 5:59 AM
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Globenewswire Inc · May 26, 2026, 11:15 PM